PE20141472A1 - Composicion farmaceutica que comprende cloruro de isometamidium en solucion para el tratamiento de la tripanosomiasis en animales - Google Patents
Composicion farmaceutica que comprende cloruro de isometamidium en solucion para el tratamiento de la tripanosomiasis en animalesInfo
- Publication number
- PE20141472A1 PE20141472A1 PE2014001030A PE2014001030A PE20141472A1 PE 20141472 A1 PE20141472 A1 PE 20141472A1 PE 2014001030 A PE2014001030 A PE 2014001030A PE 2014001030 A PE2014001030 A PE 2014001030A PE 20141472 A1 PE20141472 A1 PE 20141472A1
- Authority
- PE
- Peru
- Prior art keywords
- trypanosomiasis
- animals
- treatment
- solution
- pharmaceutical composition
- Prior art date
Links
- QNZJTSGALAVCLH-UHFFFAOYSA-N Isometamidium chloride Chemical compound [Cl-].C12=CC(\N=N\NC=3C=C(C=CC=3)C(N)=N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QNZJTSGALAVCLH-UHFFFAOYSA-N 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 title abstract 2
- 229950004591 isometamidium chloride Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000002311 trypanosomiasis Diseases 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical class [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Communication Control (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) CLORURO DE ISOMETAMIDIUM MICRONIZADO A UNA CONCENTRACION DE 1 A 4% (P/V); B) ISOPROPILIDENOGLICEROL O GLICERINFORMAL A UNA CONCENTRACION DE 40 A 95% (P/V); C) UN POLIOL A UNA CONCENTRACION DE 0 A 50% (P/V); D) 15-HIDROXIESTEARATO DE POLIETILENGLICOL A UNA CONCENTRACION DE 1 A 5% (P/V); E) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES EN SOLUCION TALES COMO i) PROPIL GALATO ENTRE 0,02 Y 0,05%, ii) POLIVINILPIRROLIDONA ENTRE 0,5 Y 5%, iii) N-METIL-2-PIRROLIDONA ENTRE 1 Y 20%, Y iv) 2-(2-ETOXIETOXI)ETANOL ENTRE 1 Y 10%. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA TRIPANOSOMIASIS Y ELIMINACION DE PARASITOS GASTROINTESTINALES Y PULMONARES EN ANIMALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201230092A ES2416004B1 (es) | 2012-01-24 | 2012-01-24 | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141472A1 true PE20141472A1 (es) | 2014-11-05 |
Family
ID=46963763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001030A PE20141472A1 (es) | 2012-01-24 | 2012-07-19 | Composicion farmaceutica que comprende cloruro de isometamidium en solucion para el tratamiento de la tripanosomiasis en animales |
Country Status (16)
| Country | Link |
|---|---|
| AP (1) | AP2014007798A0 (es) |
| AR (1) | AR089037A1 (es) |
| BR (1) | BR112014016926A8 (es) |
| CL (1) | CL2014001780A1 (es) |
| CO (1) | CO6990714A2 (es) |
| CR (1) | CR20140278A (es) |
| DO (1) | DOP2014000161A (es) |
| EC (1) | ECSP14010152A (es) |
| ES (1) | ES2416004B1 (es) |
| GT (1) | GT201400159A (es) |
| MA (1) | MA35868B1 (es) |
| MX (1) | MX2014008172A (es) |
| NI (1) | NI201400075A (es) |
| PE (1) | PE20141472A1 (es) |
| UY (1) | UY34479A (es) |
| WO (1) | WO2013110830A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2024008B (en) * | 1978-06-28 | 1983-02-16 | Merck & Co Inc | Compositions for treating trypanosomiasis infections |
| GB8805286D0 (en) * | 1988-03-05 | 1988-04-07 | Schering Agrochemicals Ltd | Trypanocides |
| US5496830A (en) * | 1994-09-14 | 1996-03-05 | Johns Hopkins University | Inhibition of hemoflagellates by camptothecin compounds |
| DE19854143A1 (de) * | 1998-11-24 | 2000-05-25 | Chambord Ltd | Pharmazeutisches Präparat mit trypanozider und blutschizontozider Wirkung |
| FR2819188B1 (fr) * | 2001-01-08 | 2003-03-14 | Virbac Sa | Compositions pulverulentes ou granulees hydrosolubles, a base de phenanthridines et leurs utilisations |
| AR060926A1 (es) * | 2007-05-14 | 2008-07-23 | Ciriaco Quiroga | Solucion anestesica transparente de propofol, con baja irritacion venosa. |
| KR20080102010A (ko) * | 2007-05-17 | 2008-11-24 | 대원제약주식회사 | 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법 |
| DE102008007381A1 (de) * | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
| WO2011042565A2 (en) * | 2009-10-09 | 2011-04-14 | Instituut Voor Tropische Geneeskunde | Antiprotozoal activity |
-
2012
- 2012-01-24 ES ES201230092A patent/ES2416004B1/es not_active Expired - Fee Related
- 2012-07-19 MX MX2014008172A patent/MX2014008172A/es unknown
- 2012-07-19 PE PE2014001030A patent/PE20141472A1/es not_active Application Discontinuation
- 2012-07-19 BR BR112014016926A patent/BR112014016926A8/pt not_active Application Discontinuation
- 2012-07-19 WO PCT/ES2012/070550 patent/WO2013110830A1/es not_active Ceased
- 2012-07-19 AP AP2014007798A patent/AP2014007798A0/xx unknown
- 2012-11-29 UY UY0001034479A patent/UY34479A/es not_active Application Discontinuation
- 2012-11-29 AR ARP120104496A patent/AR089037A1/es unknown
-
2014
- 2014-06-13 CR CR20140278A patent/CR20140278A/es unknown
- 2014-06-16 CO CO14130085A patent/CO6990714A2/es unknown
- 2014-07-03 CL CL2014001780A patent/CL2014001780A1/es unknown
- 2014-07-14 DO DO2014000161A patent/DOP2014000161A/es unknown
- 2014-07-14 NI NI201400075A patent/NI201400075A/es unknown
- 2014-07-15 MA MA37215A patent/MA35868B1/fr unknown
- 2014-07-17 GT GT201400159A patent/GT201400159A/es unknown
- 2014-07-21 EC ECIEPI201410152A patent/ECSP14010152A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2014000161A (es) | 2014-08-15 |
| WO2013110830A1 (es) | 2013-08-01 |
| CO6990714A2 (es) | 2014-07-10 |
| BR112014016926A2 (pt) | 2017-06-13 |
| ES2416004A1 (es) | 2013-07-29 |
| MX2014008172A (es) | 2014-10-06 |
| MA35868B1 (fr) | 2014-12-01 |
| CR20140278A (es) | 2014-12-02 |
| AP2014007798A0 (en) | 2014-07-31 |
| AR089037A1 (es) | 2014-07-23 |
| ECSP14010152A (es) | 2015-08-31 |
| UY34479A (es) | 2013-07-31 |
| ES2416004B1 (es) | 2014-01-28 |
| BR112014016926A8 (pt) | 2017-07-04 |
| GT201400159A (es) | 2015-11-19 |
| CL2014001780A1 (es) | 2014-10-24 |
| NI201400075A (es) | 2015-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| DOP2015000170A (es) | Compuestos químicos | |
| EA201290116A1 (ru) | Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| BR112015007592A2 (pt) | composições de enalapril | |
| MX2015003732A (es) | Tratamiento de enfermedad de alzheimer leve y moderada. | |
| CL2012002358A1 (es) | Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12. | |
| CY1118645T1 (el) | Χρηση pidotimod στη θεραπεια της ψωριασης | |
| PE20141472A1 (es) | Composicion farmaceutica que comprende cloruro de isometamidium en solucion para el tratamiento de la tripanosomiasis en animales | |
| MX2017007856A (es) | Composicion para el cuidado bucal. | |
| EA201500128A1 (ru) | Педиатрические жидкие композиции для перорального введения, содержащие непадутант | |
| EA201500368A1 (ru) | Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии | |
| RU2012100120A (ru) | Акарицидная фармацевтическая композиция на основе соли четвертичного фосфония, замещенного динитробензофураксана и ксимедонгидрохлорида | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
| CU20160048A7 (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio | |
| CU20130165A7 (es) | Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos | |
| IN2013MU02587A (es) | ||
| IN2013MU02585A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |